Nykode Therapeutics (NYKD) DNB Carnegie Nordic Healthcare Conference presentation summary

Strategic focus and financial position

• Specializes in antigen-specific precision immunotherapy for oncology and autoimmune diseases, leveraging APC-targeting technology.

• Prioritizes reaching key inflection points by 2027 across core assets, with a cash position of $60.3M as of December 31, 2025.

• Cash runway extends into 2028–2029, supporting major clinical milestones and ongoing R&D.

Oncology pipeline and clinical progress

• Abi-suva targets HPV16+ cancers, with a focus on head and neck squamous cell carcinoma (HNSCC) and expansion to other HPV16+ tumors.

• Demonstrates strong and consistent clinical effects, with ORR up to 39% in combination with checkpoint inhibitors, outperforming historical controls.

• Shows prolonged overall survival in cervical cancer (24.7 months in PD-L1+ patients) and robust monotherapy efficacy in premalignant cervical lesions.

• Abili-T randomized trial in 1L r/m HNSCC is enrolling up to 100 patients, with interim analysis expected in 2027.

Individualized Neoantigen Therapy (INT)

• VB10.NEO platform delivers fully personalized cancer vaccines using proprietary AI-driven neoantigen selection.

• Achieved 100% vaccine-induced immune responses in clinical trials, with robust supply chain and competitive 6.4-week turnaround time.

• DNA-based approach offers lower complexity and cost compared to mRNA alternatives.